A Phase 1 interventional study of DWP212525 XXmg and DWP212525 placebo in Autoimmune Diseases, sponsored by Daewoong Pharmaceutical Co. LTD.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Autoimmune Diseases with a site in Korea, Republic of — 10 open to participants now, 14 under way, 9 of them phase 3. Autoimmune Diseases · Korea, Republic of.
Among the 32 studies in Autoimmune Diseases with a site in Korea, Republic of, this one is the 24th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 1, reaches primary completion later than 2 of the 13 other live ones, and was the 27th registered.
803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.
Browse Autoimmune Diseases studies →10 of the 32 studies in Autoimmune Diseases with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Australia and 17 more countries
Ages 18+
Jade Biosciences, Inc. · Sites in Korea, Republic of, United States, Australia and 2 more countries
Ages 18–60
LucasBio · Sites in Korea, Republic of
Ages 19+
Takeda · Sites in Korea, Republic of, United States, Australia and 12 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Korea, Republic of, United States, Argentina and 6 more countries
Ages 18–100
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 19 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 40 across 542 interventional studies indexed under Autoimmune Diseases.
Median enrollment 361 across the 28 interventional studies, 98 across the 4 observational. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 32 have an industry lead sponsor. The 10 most frequent:
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Daewoong Pharmaceutical Co. LTD. has 1 study filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Autoimmune Diseases with a site in Korea, Republic of that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT06736587Daewoong Pharmaceutical Co. LTD.Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers | 2026-12-30 |
| NCT07679412LucasBioEvaluation of Safety and Efficacy of Autologous LB-DTK-CMV in Patients With Antiviral-Resistant and Refractory Cytomegalovirus Retinitis. | 2027-08-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 32 studies in Autoimmune Diseases with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The safety and tolerability of single and multiple administration of DWP212525
The safety and tolerability of single and multiple administration of DWP212525 will be evaluated in healthy adult volunteers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
Drug: DWP212525 XXmg · Drug: DWP212525 placebo
DWP212525 XXmg
DWP212525 placebo
PK profiles of DWP212525
Area under the plasma drug concentration-time curve from 0 to last
Time frame: Day 1
PK profiles of DWP212525
The maximum or peak concentration between zero and dosing interval
Time frame: Day 1
PK profiles of DWP212525
Time of maximum concentration
Time frame: Day 1
Safety profiles
AE, SAE, etc.
Time frame: Day 1
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.
Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 24 months is above that.
Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD. →